Searchable abstracts of presentations at key conferences in endocrinology

ea0038p161 | Neoplasia, cancer and late effects | SFEBES2015

Imaging and evaluating side effects of antiandrogen therapy

Tommasini-Ghelfi Serena , Dart D Alwyn Dart , Bevan Charlotte

Androgens are required for normal development and fertility. They have a vital role in tissues such as the reproductive tract, the brain, muscle and bone. Prostate cancer (PCa) is the most prevalent malignancy in western males: it is dependent upon circulating androgens and the therapies currently available aim to reduce synthesis of circulating androgens and/or inhibit the pathway using antiandrogens. Therapies inhibiting androgen signalling, and in particular the androgen re...

ea0042oc3 | (1) | Androgens2016

Novel trifluoromethylated enobosarm analogues show very potent antiandrogen activity in prostate cancer cells, and cells with acquired bicalutamide resistance whilst maintaining tissue selectivity in vivo

Dart Alwyn , Kandil Sahar , Tommasini-Ghelfi Serena , Bevan Charlotte , Jiang Wenguo , Westwell Andrew D.

Prostate cancer often develops anti-androgen resistance, possibly via AR mutations which change AR antagonists to agonists. There is an urgent need for novel therapies which ideally show increased anticancer activity, whilst overcoming current drug resistance. Enobosarm has anabolic effects on muscle and bone tissues whilst having no effect on the prostate – often used to combat cachexia in advanced lung cancer. Here we describe the activity of novel chemically modified E...

ea0042oc15 | (1) | Androgens2016

In vivo imaging reveals prostate pathology in the PTEN knockout murine model of prostate cancer

Bhatti Alysha , de Almeida Gilberto Serrano , Ghelfi Serena Tommasini , Dart Alwyn , Varela-Carver Anabel , Bevan Charlotte L.

Prostate cancer (PCa) is driven by the androgen receptor (AR) signalling axis and begins with prostatic intraepithelial neoplasia (PIN), progressing to invasive adenocarcinoma and eventually metastatic disease. It is treated with androgen deprivation therapies, to which, in late-stage disease, tumours often become resistant and proliferation occurs in a low androgen environment. Mutation of the PTEN tumour suppressor gene is found in approximately 30% of primary human prostate...

ea0054is1 | (1) | NuclearReceptors2018

MicroRNA regulation of androgen signalling

Fletcher Claire E , Sita-Lumsden Ailsa , Dart Alwyn , Shibakawa Akifumi , Sulpice Eric , Combe Stephanie , Leach Damien A , de Bono Johann , Lupold SE , McGuire SE , Gidrol Xavier , Bevan Charlotte L

Androgens initially drive prostate tumour growth. Although in advanced disease there is no longer dependence on circulating androgens, the androgen receptor (AR) remains a key driver of this lethal stage thus new ways to inhibit its activity are required. MicroRNAs play vital roles in prostate cancer (PCa) development, progression and metastasis. Previous studies have examined microRNAs dysregulated in PCa, and also identified androgen-regulated microRNAs. We approached microR...